Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer
Phase III Clinical Trial
A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)